A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Development of 68Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET
Tekijät: Lambidis Elisavet, Chen Chun-Chieh, Baikoghli Mo, Imlimthan Surachet, Khng You C, Sarparanta Mirkka, Cheng R Holland, Airaksinen Anu J
Julkaisuvuosi: 2022
Journal: Molecular Pharmaceutics
Tietokannassa oleva lehden nimi: Molecular pharmaceutics
Lehden akronyymi: Mol Pharm
Vuosikerta: 19
Numero: 8
Aloitussivu: 2971
Lopetussivu: 2979
ISSN: 1543-8384
eISSN: 1543-8392
DOI: https://doi.org/10.1021/acs.molpharmaceut.2c00359
Verkko-osoite: https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.2c00359
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/176581895
Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery of higher cargo concentrations to diseased sites. Virus-like particles (VLPs) can efficiently be used for targeted delivery purposes. VLPs are derived from the coat proteins of viral capsids. They are self-assembled, biodegradable, and homogeneously distributed. In this study, hepatitis E virus (HEV) VLP derivatives, hepatitis E virus nanoparticles (HEVNPs), were radiolabeled with gallium-68, and consequently, the biodistribution of the labeled [68Ga]Ga-DOTA-HEVNPs was studied in mice. The results indicated that [68Ga]Ga-DOTA-HEVNPs can be considered as promising theranostic nanocarriers, especially for hepatocyte-targeting therapies.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
